敏捷医疗完成数亿元B轮融资，明熙资本领投

Core Insights - Agile Medical Technology (Suzhou) Co., Ltd. has completed a multi-hundred million RMB Series B financing round, led by Mingxi Capital, with participation from Yuanhe Holdings, Licheng Investment, and Nantong Investment Management, along with continued investment from existing shareholders [1][2] - The funds will be primarily used for three key areas: deepening global commercialization, accelerating the R&D iteration of surgical robot product lines, and further upgrading cutting-edge technology platforms [1] Company Developments - The core product, AGIBOT® laparoscopic surgical robot, is expected to receive approval from the National Medical Products Administration (NMPA) by March 2025, and has already completed over 100 clinical applications in top-tier hospitals [1] - Agile Medical has established a comprehensive capability loop from R&D to market, with a production base in Suzhou capable of manufacturing 100 systems and 20,000 surgical instruments annually, along with professional user training for hundreds of individuals each year [1] Innovation and Market Position - As an innovator in China's surgical robot industry, Agile Medical focuses on user needs and continues to build a technological foundation based on "AGI+BOT" through independent innovation [2] - The recent financing round reaffirms the capital market's confidence in the company's development path of "innovative technology + inclusive healthcare" [2]